替格瑞洛用于冠心病合并肾功能不全PCI术后的价值  

The value of tegrel after PCI for coronary heart disease with renal insufficiency

作　　者：杜涛[1] Du Tao(The Second People's Hospital of Lanzhou city Lanzhou,Gansu 730030,China)

机构地区：[1]兰州市第二人民医院,甘肃兰州730030

出　　处：《西藏医药》2023年第4期17-20,共4页Tibetan Medicine

摘　　要：目的研究替格瑞洛用于冠心病合并肾功能不全PCI术后的价值。方法选取我院2020年10月~2022年10月收治的冠心病合并慢性肾功能不全患者130例。随机分为实验组(n=65)和对照组(n=65),两组术后均口服阿司匹林,对照组在术后口服氯吡格雷,实验组在术后口服替格瑞洛,比较两组治疗前后血凝功能、氧化应激指标、免疫功能及两组用药期间不良事件发生情况。结果治疗后,实验组FIB、MRAP水平显著低于治疗前及对照组(P<0.05);实验组MDA显著低于治疗前及对照组,SOD显著高于治疗前和对照组(P<0.05);治疗后实验组CD3+、CD4+显著高于治疗前及对照组,CD8+、IL-6、IL-8显著低于治疗前及对照组(P<0.05);实验组不良事件发生率为16.92%,对照组32.31%(P<0.05)。结论替格瑞洛联合阿司匹林用于冠心病合并慢性肾功能不全患者PCI术后可显著改善其凝血功能。Objective:To study the value of ticagrelor in patients with coronary heart disease combined with renal insufficiency after PCI.Methods:A total of 130 patients with coronary heart disease combined with chronic renal insufficiency admitted to our hospital from October 2020 to October 2022 were selected.The two groups were randomly divided into experimental group(n=65)and control group(n=65).Both groups were given oral aspirin after surgery.The control group was treated with clopidogrel combined with aspirin after surgery,while the experimental group was treated with oral ticagrelor after surgery.The blood coagulation function,oxidative stress indicators,immune function and the occurrence of adverse events between the two groups were compared before and after treatment.Results:After treatment,the levels of FIB and MRAP in the experimental group were significantly lower than t before treatment and in the control group(P<0.05).MDA in the experimental group was significantly lower than before treatment and t in the control group,and SOD was significantly higher than before treatment and in the control group(P<0.05).After treatment,the levels of CD3+and CD4+in the experimental group were significantly higher than those before treatment and in the control group,and the levels of CD8+,IL-6,and IL-8 were significantly lower than those before treatment and in the control group(P<0.05).The incidence of adverse events was 16.92%in the experimental group,and 32.31%in the control group(P<0.05).Conclusion:ticagrelorcombined with aspirin can significantly improve the coagulation function of patients with coronary heart disease and chronic renalinsufficiency after PCI.

关 键 词：冠心病 经皮冠状动脉介入治疗 替格瑞洛 慢性肾功能不全 

分 类 号：R541.4[医药卫生—心血管疾病] R692[医药卫生—内科学]